Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Nafarelin
Drug ID BADD_D01513
Description Nafarelin is a potent synthetic agonist of gonadotropin-releasing hormone with 3-(2-naphthyl)-D-alanine substitution at residue 6. Nafarelin has been used in the treatments of central precocious puberty and endometriosis.
Indications and Usage For treatment of central precocious puberty (true precocious puberty, GnRH-dependent precocious precocity, complete isosexual precocity) in children of both sexes and for the treatment of endometriosis.
Marketing Status approved
ATC Code H01CA02
DrugBank ID DB00666
KEGG ID D08241
MeSH ID D017274
PubChem ID 25077405
TTD Drug ID D08WYM
NDC Product Code Not Available
UNII 1X0094V6JV
Synonyms Nafarelin | Synarel | RS-94991-298 | RS 94991 298 | RS94991298 | Nafarelin Acetate | Nafarelin Acetate, Hydrate | Nafarelin Monoacetate
Chemical Information
Molecular Formula C66H83N17O13
CAS Registry Number 76932-56-4
SMILES CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NCC(=O)N)NC(=O)C(CC2=CC3=CC=CC=C3C=C 2)NC(=O)C(CC4=CC=C(C=C4)O)NC(=O)C(CO)NC(=O)C(CC5=CNC6=CC=CC=C65)NC(=O)C(CC7=CN=C N7)NC(=O)C8CCC(=O)N8
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Urinary incontinence20.02.02.010; 17.05.01.008--
Urticaria23.04.02.001; 10.01.06.001--
Uterine haemorrhage24.07.03.004; 21.07.01.005--
Vaginal discharge21.08.02.002--
Vaginal haemorrhage24.07.03.005; 21.08.01.001--
Vertigo17.02.12.002; 04.04.01.003--
Visual impairment06.02.10.0130.000186%Not Available
Vomiting07.01.07.003--
Vulvovaginal dryness21.08.02.003--
Weight decreased13.15.01.005--
Weight increased13.15.01.006--
Osteopenia15.02.03.003; 14.04.04.004--Not Available
Pituitary haemorrhage24.07.04.009; 17.08.01.019; 05.03.04.005--Not Available
Deep vein thrombosis24.01.02.003--Not Available
Acute coronary syndrome24.04.04.011; 02.02.02.015--Not Available
Nasal discomfort22.12.03.012--Not Available
Musculoskeletal discomfort15.03.04.001--Not Available
Affect lability19.04.01.001--Not Available
Haemorrhage24.07.01.0020.000279%Not Available
Disturbance in sexual arousal19.08.04.003--Not Available
Hot flush24.03.01.005; 21.02.02.001; 08.01.03.027--
Malnutrition14.03.02.004--Not Available
Mental disorder19.07.01.002--Not Available
Decreased appetite14.03.01.005; 08.01.09.028--
Pituitary tumour benign05.03.05.003; 16.37.02.001--Not Available
Effusion08.01.03.0520.000466%Not Available
Cystitis noninfective20.03.02.001--
Liver injury12.01.17.012; 09.01.07.022--Not Available
Traumatic liver injury12.01.17.027; 09.01.08.010--Not Available
Adnexal torsion21.11.02.0120.000373%Not Available
The 4th Page    First    Pre   4 5    Next   Last    Total 5 Pages